MARTINSRIED, Germany, Nov. 13, 2006 (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) announced today that its partner Boehringer Ingelheim has exercised an option for optimizing a therapeutic HuCAL antibody and has acquired an exclusive license for this project. The antibody identified by Boehringer Ingelheim at its research site in Vienna is directed against a cancer disease-related target molecule. MorphoSys will optimize the antibody in accordance with the requirements of the partner and will receive additional research payments. Further financial details were not disclosed.
